Search company, investor...

Compare Poniard Pharmaceuticals vs Alaunos Therapeutics

Customers evaluate the quality of Poniard Pharmaceuticals's products using the following success metrics.

Overview

Poniard Pharmaceuticals is 40 yrs old and is based in United States.

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration resistant prostate cancers (also known as hormone refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Alaunos Therapeutics

Alaunos Therapeutics is 21 yrs old and is based in United States.

Alaunos Therapeutics (NASDAQ: TCRT) is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for patient treatment. Alaunos Therapeutics was formerly known as Alaunos Therapeutics. It was founded in 2003 and is based in Boston, Massachusetts.

Founded Year